Partners Eli Lilly and AstraZeneca got a leap ahead in the BACE inhibitor race as they secure a fast-track designation from the FDA for Phase III candidate…

The privately owned Dublin, Ireland-based DS Biopharma has spun out a company from its ranks in order for it to focus specifically on scarring diseases, while…

Move over Sanofi, your original $9.3 billion bid and even your second, sweetened offer has been blown out of the water by the $14 billion being put on the…

A biotech borne out of a JV between Bayer’s new research deals arm and CRISPR Therapeutics will start operations at life sciences hub Kendall Square in…

Nordic Nanovector has completed enrollment of the first cohorts of the pre-dosed arms of its non-Hodgkin lymphoma trial.

Startup Nutrinia has lined up an impressive roster of investors to back what has been a long elusive achievement—the development of oral insulin.

Caribou Biosciences has discovered patterns in the way different cell types respond to being cut via CRISPR-Cas9 genome editing.

Small cap Auris Medical Holding has missed its co-primary endpoints in a key Phase III trial after it failed to beat placebo in treating patients with tinnitus.